Industry news that matters to you.  Learn more

Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kits

Invivoscribe® Technologies Inc., an international company with decades of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® and personalized molecular medicine®, announces today its long-term collaboration agreement with Illumina® Inc., to develop and commercialize in vitro diagnostic (IVD) assays for the next-generation sequencing (NGS) MiSeqDx® platform. This agreement allows Invivoscribe to bring IVD assays through the FDA, together with the associated bioinformatics software, for sale and distribution in the US.

Illumina Selects BioDiscovery’s NxClinical Software for Data Visualization, Management and Interpretation for its CytoSeq ™ assay, an NGS-based Solution for Detection of CNVs, AOH, and SNVs

BioDiscovery, Inc., a leader in innovative genomic data analysis software solutions recently announced a collaborative agreement with Illumina Inc. (NASDAQ: ILMN) to provide BioDiscovery’s NxClinical software as the secondary data analysis and management tool for Illumina’s CytoSeq™ assay. The NxClinical software will be offered with the CytoSeq product to provide an easy-to-use interactive tool for visualization and interpretation of genomic events.

SCIEX Announces OneOmics Collaborators

SCIEX, a global leader in life science analytical technologies, recently announced collaborators in the OneOmics™ project, an exclusive partnership between Illumina and SCIEX that integrates SWATH™ Acquisition based next-generation proteomics (NGP) and next-generation sequencing (NGS) data on the BaseSpace® cloud computing environment. Advaita Bioinformatics, The Institute for Systems Biology (ISB) and researchers at Yale University have each developed cloud-based applications and libraries that utilize SWATH Proteomics data in novel ways allowing researchers to analyze and compare proteomics and genomics data. This effort furthers the OneOmics project’s goal of eliminating the informatics barriers that exist between different Omics disciplines.

Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery

Cypher Genomics, Inc., the genome informatics company, recently announced a co-promotion agreement with Illumina to facilitate the development of genomic-based biomarkers from whole genome sequence data for precision medicine and clinical trials. Cypher Genomics and Illumina will jointly offer pharmaceutical companies, through Illumina’s sales force, a solution including Illumina’s market leading sequencing technology, the NextBio platform for data analytics and storage, and Cypher Genomics’ biomarker discovery service, called Coral. Cypher Genomics technology reduces the signal-to-noise in genomic information to uncover important biomarkers in sample sizes typical of early stage drug development studies.

Illumina to Provide Next-Generation Sequencing (NGS) Technologies to Quest Diagnostics

Illumina, Inc. (NASDAQ:ILMN) recently announced it has entered into a multi-year licensing agreement with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, related to the use of Illumina’s next-generation sequencing technology for clinical laboratory testing.